Cortaid Intensive Therapy Cooling Spray (1% hydrocortisone), 2 FL OZ (59 mL) spray bottle, OTC, D...
FDA Drug Recall #D-0084-2019 — Class II — August 24, 2018
Recall Summary
| Recall Number | D-0084-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 24, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Valeant Pharmaceuticals North America LLC |
| Location | Bridgewater, NJ |
| Product Type | Drugs |
| Quantity | 18,408 bottles |
Product Description
Cortaid Intensive Therapy Cooling Spray (1% hydrocortisone), 2 FL OZ (59 mL) spray bottle, OTC, Distributed by: Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807, UPC code 301875518028
Reason for Recall
CGMP deviations: Notice received from supplier of a voluntary recall of all their nasal products and baby oral gels due to the possibility of microbial contamination. No positive results for the firm's products. were obtained. After the firm review, cGMP deviations ere evident.
Distribution Pattern
Product was distributed throughout the United States
Lot / Code Information
Lot #: 171205E, 171951E, Exp 5/19; 173365K, Exp 10/19
Other Recalls from Valeant Pharmaceuticals North America...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0487-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 120 mg, p... | Jan 30, 2019 |
| D-0488-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 180 mg, p... | Jan 30, 2019 |
| D-0490-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 300 mg, p... | Jan 30, 2019 |
| D-0489-2019 | Class III | Cardizem CD (diltiazem HCl) capsules, 240 mg, p... | Jan 30, 2019 |
| D-0491-2019 | Class III | Diltiazem HCl CD capsules, 360 mg, 90-count bot... | Jan 30, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.